A Bone Drug That Isn't Being Given for Her Bones
Her DEXA scan is normal. She still qualifies for adjuvant zoledronic acid — not to protect bone density, but because a large meta-analysis found the drug itself lowers breast cancer recurrence in postmenopausal women, a genuinely separate indication her own team keeps conflating with bone protection.
Judith A., a 68-year-old avid gardener who measures her year by tomato harvests, came to her adjuvant planning visit expecting a straightforward conversation about letrozole and was surprised when zoledronic acid came up as well — surprised specifically because her own recent bone density scan came back normal, and she had, not unreasonably, assumed a bone-protective drug was only relevant to a patient whose bones actually needed protecting.
That assumption reflects a real and common conflation of two genuinely separate indications for the same drug class. Zoledronic acid is used routinely to counter the bone density loss aromatase inhibitors cause over years of estrogen deprivation — a legitimate, familiar use, and not the reason it's being raised for Judith, whose DEXA scan shows no such loss to protect against yet. The separate indication is a large EBCTCG meta-analysis, pooling individual patient data across more than a dozen randomized trials, that found adjuvant bisphosphonate therapy reduces breast cancer recurrence and breast-cancer mortality specifically in postmenopausal women — a benefit the analysis found concentrated entirely in the postmenopausal subgroup, with no comparable effect, and possibly a slightly adverse trend, in premenopausal patients, a divergence the investigators attributed to the different bone marrow microenvironment estrogen deprivation creates rather than to any direct antitumor action of the drug elsewhere in the body. Judith's bone density has nothing to do with whether this second indication applies to her; her menopausal status is the entire basis for it, and a normal DEXA scan doesn't remove her from the population the meta-analysis actually studied.
Adjuvant planning visit
I want to be precise with her about why this drug is being recommended, because I think the confusion she raised is common and worth correcting directly rather than glossing over: the EBCTCG recurrence-reduction benefit applies to her because she's postmenopausal, full stop — her normal bone density is genuinely irrelevant to this specific indication.
Agreed on the mechanism, and I'd add the practical dosing note that follows from it: because this use is about recurrence reduction rather than bone protection, the dosing interval used in the EBCTCG-supporting trials is generally less frequent than the schedule used for pure osteoporosis prevention — twice yearly rather than the more frequent dosing sometimes used for active bone-density loss.
Her recent extraction healed without complication, which is reassuring, but I'd still recommend she avoid any elective dental extractions for the duration of bisphosphonate therapy if possible, and complete any planned dental work before starting rather than during — osteonecrosis of the jaw is uncommon at this drug's dose and interval, but it's not zero, and prevention is simpler than management once someone is already on therapy.
Agreed: zoledronic acid twice yearly alongside letrozole, with elective dental work completed before starting therapy per the consulting dentist's recommendation, and the distinction between the two indications — recurrence reduction versus bone protection — written into her own patient education materials so the confusion doesn't recur at a future visit with a different provider.